Dolby Laboratories (NYSE:DLB) Releases FY 2027 Earnings Guidance

Dolby Laboratories (NYSE:DLB – Get Free Report) issued an update on its FY 2027 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 4.270-4.420 for the period, compared to the consensus estimate of 4.340. The company issued revenue guidance of $1.4 billion, compared to the consensus revenue estimate of $1.5 billion. Dolby Laboratories also updated its Q1 2027 guidance to 0.410-0.560 EPS.

Dolby Laboratories Price Performance

NYSE:DLB traded down $2.56 during trading hours on Tuesday, reaching $58.60. The company had a trading volume of 3,929,316 shares, compared to its average volume of 841,243. Dolby Laboratories has a 1-year low of $48.26 and a 1-year high of $69.95. The firm has a market cap of $5.49 billion, a PE ratio of 24.94 and a beta of 0.79. The business’s 50 day moving average price is $60.97 and its 200-day moving average price is $59.43.

Dolby Laboratories (NYSE:DLB – Get Free Report) last issued its quarterly earnings data on Tuesday, November 17th. The electronics maker reported $1.25 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.05. The business had revenue of $373.54 million for the quarter, compared to analysts’ expectations of $372.76 million. Dolby Laboratories had a net margin of 16.70% and a return on equity of 11.08%. Dolby Laboratories has set its Q1 2027 guidance at 0.410-0.560 EPS and its FY 2027 guidance at 4.270-4.420 EPS. On average, analysts expect that Dolby Laboratories will post 3.23 earnings per share for the current fiscal year.

Dolby Laboratories announced that its board has approved a stock buyback plan on Thursday, July 30th that permits the company to buy back $350 million in outstanding shares. This buyback authorization permits the electronics maker to buy up to 7% of its shares through open market purchases. Stock buyback plans are generally a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Weiss Ratings raised shares of Dolby Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, September 9th. Wall Street Zen downgraded Dolby Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Zacks Research raised Dolby Laboratories from a “strong sell” rating to a “hold” rating in a report on Friday. Finally, Rosenblatt Securities cut their price objective on Dolby Laboratories from $85.00 to $80.00 and set a “buy” rating for the company in a research report on Monday. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $85.00.

Read Our Latest Report on DLB

Insider Transactions at Dolby Laboratories

In related news, CAO Ryan Nicholson sold 1,183 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $65.28, for a total transaction of $77,226.24. Following the completion of the transaction, the chief accounting officer owned 34,453 shares in the company, valued at $2,249,091.84. This represents a 3.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP John Couling sold 7,667 shares of the firm’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $58.78, for a total transaction of $450,666.26. Following the completion of the transaction, the senior vice president directly owned 166,803 shares in the company, valued at $9,804,680.34. This represents a 4.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 16,517 shares of company stock valued at $995,963 in the last three months. Corporate insiders own 37.93% of the company’s stock.

Latest Dolby Laboratories News

Here’s some of the latest news about DLB:

  • Positive Sentiment: Fiscal Q4 2026 EPS was $1.25, above the $1.20 consensus, while revenue of about $374 million slightly exceeded estimates and rose from $307 million a year earlier. Dolby Laboratories fiscal 2026 results
  • Positive Sentiment: Zacks Research made small upward revisions to several 2027–2028 EPS estimates, including its FY2028 forecast to $3.40 from $3.38, though it maintained a Hold rating.
  • Neutral Sentiment: Trading volume was substantially above its average, suggesting heightened investor activity around the earnings release; the reports do not establish what drove the market’s reaction.

About Dolby Laboratories

(Get Free Report)

Dolby Laboratories, Inc. develops audio and imaging technologies used in entertainment and consumer electronics. Its offerings include Dolby Atmos immersive audio, Dolby Vision high-dynamic-range imaging, and technologies for encoding, delivering and reproducing sound and video. The company licenses its technologies to manufacturers and content businesses across areas such as film, television, streaming, gaming and mobile devices. Dolby also supports cinema experiences through technologies and services including Dolby Cinema.

Read More

Earnings History and Estimates for Dolby Laboratories (NYSE:DLB)

Receive News & Ratings for Dolby Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dolby Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.